SCHEMBL211489

SCHEMBL211489

Nc1c(Cl)nc2ccccc2c1NCc1ccc(CNC(=O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
RAD52 P43351 1/20 0.51
KMT2A Q03164 1/20 0.51
APP P05067 9/20 0.48
ELANE P08246 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
PDE5A O76074 1/20 0.43
ACHE P22303 3/20 0.43
BCHE P06276 1/20 0.43
BACE1 P56817 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5073659 0.92 APP (0.48) POLBRAD52KMT2AAPPELANE
SCHEMBL13968056 0.88 KMT2A (0.66) POLBRAD52KMT2AAPPPDE5A
SCHEMBL29381485 0.85 KMT2A (0.50) POLBRAD52KMT2AAPPBCHE
SCHEMBL21013099 0.85 KMT2A (0.50) POLBRAD52KMT2AAPPBCHE
SCHEMBL28872741 0.85 POLB (0.46) POLBRAD52KMT2AAPPELANE
SCHEMBL21632108 0.85 BCHE (0.47) POLBRAD52CYP1A2CYP2D6CYP2C9
SCHEMBL8121604 0.83 KMT2A (0.55) POLBRAD52KMT2AAPPPDE5A
SCHEMBL17675656 0.82 ACHE (0.52) POLBRAD52ACHEBCHEKDM4E
SCHEMBL213444 0.81 APP (0.62) POLBRAD52KMT2AAPPCYP1A2
SCHEMBL27744435 0.81 KMT2A (0.42) POLBRAD52KMT2AAPPELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981670-B2 Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2024-05-14 US disclosed
EP-4257198-A2 ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF Dynavax Technologies Corporation (US) 2023-10-11 EP disclosed
EP-3672969-B1 ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF DYNAVAX TECH CORP (US) 2023-07-05 EP disclosed
US-20220033400-A1 ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF DYNAVAX TECHNOLOGIES CORPORATION (US) 2022-02-03 US disclosed
US-11124510-B2 Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2021-09-21 US disclosed
US-20210213010-A1 TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS DANMARKS TEKNISKE UNIVERSITET (DK) 2021-07-15 US disclosed
EP-3827002-A1 TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS Torque Therapeutics, Inc. (US) 2021-06-02 EP disclosed
EP-3710059-A1 CLEAVABLE CONJUGATES OF TLR7/8 AGONIST COMPOUNDS, METHODS FOR PREPARATION, AND USES THEREOF Dynavax Technologies Corporation (US) 2020-09-23 EP disclosed
US-10722591-B2 Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof DYNAVAX TECHNOLOGIES CORPORATION (US) 2020-07-28 US disclosed
EP-3672969-A1 ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF Dynavax Technologies Corporation (US) 2020-07-01 EP disclosed
EP-3356371-A1 POLYMER CONJUGATE VACCINES The University of Chicago (US) 2018-08-08 EP disclosed
EP-3215189-A1 POLYMER ADJUVANT Oxford University Innovation Limited (GB) 2017-09-13 EP disclosed
WO-2016055812-A1 POLYMER ADJUVANT ISIS INNOVATION LIMITED (GB) 2016-04-14 WO disclosed
EP-1948173-B1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2013-07-17 EP disclosed
US-8377957-B2 Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-20120071463-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS 3M INNOVATIVE PROPERTIES COMPANY 2012-03-22 US disclosed
US-8088790-B2 Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221556-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS PFIZER INC. 2009-09-03 US disclosed
EP-1948173-A2 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS Coley Pharmaceutical Group, Inc. (US) 2008-07-30 EP disclosed
WO-2007056112-A2 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10722591-B2 Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof TLR7, TLR8, TLR9 POLB 2215/4885RAD52 1106/4885KMT2A 1012/4885
US-11981670-B2 Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof TLR7, TLR8, TLR3 POLB 2689/4885RAD52 3255/4885KMT2A 831/4885
US-20210213010-A1 TLR7/8 AGONISTS AND LIPOSOME COMPOSITIONS TLR7, TLR9, TLR8 POLB 4256/4885RAD52 4108/4885KMT2A 699/4885
US-20090221556-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS IFNG, IL2, IRF3 POLB 1616/4885RAD52 483/4885KMT2A 2108/4885
US-11124510-B2 Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof TLR7, TLR8, TLR3 POLB 2689/4885RAD52 3255/4885KMT2A 831/4885
US-20120071463-A1 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS IFNG, IL2, IRF3 POLB 1616/4885RAD52 483/4885KMT2A 2108/4885
US-20220033400-A1 ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF TLR7, TLR8, TLR3 POLB 2689/4885RAD52 3255/4885KMT2A 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.